Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Age-stratified infection fatality rate of COVID-19 in the non-elderly population
Angelo Maria Pezzullo, Cathrine Axfors, Despina G. Contopoulos‐Ioannidis, et al.
Environmental Research (2022) Vol. 216, pp. 114655-114655
Open Access | Times Cited: 95

Showing 1-25 of 95 citing articles:

Estimates of COVID‐19 deaths in Mainland China after abandoning zero COVID policy
John P. A. Ioannidis, Francesco Zonta, Michael Levitt
European Journal of Clinical Investigation (2023) Vol. 53, Iss. 4
Open Access | Times Cited: 44
Excess mortality across countries in the Western World since the COVID-19 pandemic: ‘Our World in Data’ estimates of January 2020 to December 2022
Saskia Mostert, Marcel Hoogland, Minke H. W. Huibers, et al.
BMJ Public Health (2024) Vol. 2, Iss. 1, pp. e000282-e000282
Closed Access | Times Cited: 16
Flaws and uncertainties in pandemic global excess death calculations
John P. A. Ioannidis, Francesco Zonta, Michael Levitt
European Journal of Clinical Investigation (2023) Vol. 53, Iss. 8
Open Access | Times Cited: 22
Long COVID as a functional somatic symptom disorder caused by abnormally precise prior expectations during Bayesian perceptual processing: A new hypothesis and implications for pandemic response
Ari R. Joffe, April Elliott
SAGE Open Medicine (2023) Vol. 11
Open Access | Times Cited: 22
COVID-19 mRNA Vaccines: Lessons Learned from the Registrational Trials and Global Vaccination Campaign
M. Nathaniel Mead, Stephanie Seneff, Russ Wolfinger, et al.
Cureus (2024)
Open Access | Times Cited: 13
The Novelty of mRNA Viral Vaccines and Potential Harms: A Scoping Review
Matthew Halma, Jessica Rose, Theresa A Lawrie
J — Multidisciplinary Scientific Journal (2023) Vol. 6, Iss. 2, pp. 220-235
Open Access | Times Cited: 20
Autoimmune inflammatory reactions triggered by the COVID-19 genetic vaccines in terminally differentiated tissues
Panagis Polykretis, Alberto Donzelli, Janci C. Lindsay, et al.
Autoimmunity (2023) Vol. 56, Iss. 1
Open Access | Times Cited: 15
Variability in excess deaths across countries with different vulnerability during 2020–2023
John P. A. Ioannidis, Francesco Zonta, Michael Levitt
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 49
Open Access | Times Cited: 15
Effectiveness of a fourth SARS‐CoV‐2 vaccine dose in previously infected individuals from Austria
Alena Chalupka, Lukas Richter, Ali Chakeri, et al.
European Journal of Clinical Investigation (2023) Vol. 54, Iss. 3
Open Access | Times Cited: 15
Wearing face masks as a potential source for inhalation and oral uptake of inanimate toxins – A scoping review
Kai Kisielinski, Stefan Hockertz, Oliver Hirsch, et al.
Ecotoxicology and Environmental Safety (2024) Vol. 275, pp. 115858-115858
Open Access | Times Cited: 6
COVID-19 Modified mRNA “Vaccines”: Lessons Learned from Clinical Trials, Mass Vaccination, and the Bio-Pharmaceutical Complex, Part 1
M. Nathaniel Mead, Stephanie Seneff, Russ Wolfinger, et al.
International Journal of Vaccine Theory Practice and Research (2024) Vol. 3, Iss. 2, pp. 1112-1178
Closed Access | Times Cited: 6
Strengthening serological studies: the need for greater geographical diversity, biobanking, and data-accessibility
Arthur Menezes, Solohery Lalaina Razafimahatratra, Oghenebrume Wariri, et al.
Trends in Microbiology (2025)
Closed Access
Pediatric Gastrointestinal Tract Outcomes During the Postacute Phase of COVID-19
Dazheng Zhang, Ronen Stein, Yiwen Lu, et al.
JAMA Network Open (2025) Vol. 8, Iss. 2, pp. e2458366-e2458366
Open Access
COVID-19 Case Fatality Rate and Infection Fatality Rate from 2020 to 2023: Nationwide Analysis in Austria
Uwe Riedmann, Alena Chalupka, Lukas Richter, et al.
Journal of Infection and Public Health (2025) Vol. 18, Iss. 4, pp. 102698-102698
Open Access
A counterfactual analysis quantifying the COVID-19 vaccination impact in Sweden
Fanny Bergström, Felix Günther, Tom Britton
Vaccine (2025) Vol. 52, pp. 126870-126870
Open Access
Differential COVID-19 infection rates in children, adults, and elderly: Systematic review and meta-analysis of 38 pre-vaccination national seroprevalence studies
Cathrine Axfors, Angelo Maria Pezzullo, Despina G. Contopoulos‐Ioannidis, et al.
Journal of Global Health (2023) Vol. 13
Open Access | Times Cited: 12
Study of optimal vaccination strategies for early COVID-19 pandemic using an age-structured mathematical model: A case study of the USA
Giulia Luebben, Gilberto González‐Parra, Bishop Cervantes
Mathematical Biosciences & Engineering (2023) Vol. 20, Iss. 6, pp. 10828-10865
Open Access | Times Cited: 12
Epistemische Autoritäten
Rico Hauswald
Springer eBooks (2024)
Closed Access | Times Cited: 4
Evidence base for yearly respiratory virus vaccines: Current status and proposed improved strategies
Mariana Barosa, John P. A. Ioannidis, Vinay Prasad
European Journal of Clinical Investigation (2024) Vol. 54, Iss. 10
Open Access | Times Cited: 3
Is resisting Covid-19 vaccination a “problem”? A critical policy inquiry of vaccine mandates for healthcare workers
Claudia Chaufan, Natalie Hemsing
(2024)
Open Access | Times Cited: 2
Is society caught up in a Death Spiral? Modeling societal demise and its reversal
Michaéla C. Schippers, John P. A. Ioannidis, Matthias Luijks
Frontiers in Sociology (2024) Vol. 9
Open Access | Times Cited: 2
Estimating SARS-CoV-2 infection probabilities with serological data and a Bayesian mixture model
Benjamin Glémain, Xavier de Lamballerie, Marie Zins, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
COVID-19 Modified mRNA “Vaccines”: Lessons Learned from Clinical Trials, Mass Vaccination, and the Bio-Pharmaceutical Complex, Part 2
M. Nathaniel Mead, Stephanie Seneff, Jessica Rose, et al.
International Journal of Vaccine Theory Practice and Research (2024) Vol. 3, Iss. 2, pp. 1275-1344
Open Access | Times Cited: 2
Effectiveness of the first and second SARS-CoV-2 vaccine dose: a nationwide cohort study from Austria on hybrid versus natural immunity
Alena Chalupka, Uwe Riedmann, Lukáš Richter, et al.
Open Forum Infectious Diseases (2024) Vol. 11, Iss. 10
Open Access | Times Cited: 2
Pharmaceutical product recall and educated hesitancy towards new drugs and novel vaccines
Peter Rhodes, Peter Parry
International Journal of Risk & Safety in Medicine (2024) Vol. 35, Iss. 4, pp. 317-333
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top